Phase 2Completed
Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
A Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Tranilast in Combination With Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
- Sponsor
- Nuon Therapeutics, Inc. (Industry)
- Enrollment
- 112 enrolled
- Conditions
- Moderate to Severe Gout; Hyperuricemia
- Interventions
- Combination 400; Allopurinol; Combination 600
- Ages
- adults, older adults
- Registry
- NCT01109121
Full record on ClinicalTrials.gov
From the registry
This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.
Primary outcomes
- Percent change from baseline in serum uric acid (sUA) levels
History
Study completion
Last registry update
Primary completion
Started
Registered